Published in Am J Cardiol on September 01, 1992
Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med (2001) 4.46
Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet (1996) 3.02
Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu----Val mutation and a 403Arg----Gln mutation. Circulation (1992) 2.67
Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J Clin Invest (1993) 2.04
Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1993) 1.89
Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest (1995) 1.75
Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A (1995) 1.70
Temporal repolarization lability in hypertrophic cardiomyopathy caused by beta-myosin heavy-chain gene mutations. Circulation (2000) 1.58
Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet (2002) 1.56
Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol (1998) 1.47
R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res Cell Motil (2000) 1.44
Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. J Am Coll Cardiol (2000) 1.44
The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil (1997) 1.40
Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol (2000) 1.35
Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. Circulation (1995) 1.34
Evidence of genetic heterogeneity in five kindreds with familial hypertrophic cardiomyopathy. Circulation (1992) 1.29
Novel association of hypertrophic cardiomyopathy, sensorineural deafness, and a mutation in unconventional myosin VI (MYO6). J Med Genet (2004) 1.16
Structural and functional responses of mammalian thick filaments to alterations in myosin regulatory light chains. J Struct Biol (1998) 1.12
Reliability of the evoked response in determining the paced ventricular rate and performance of the QT or rate responsive (TX) pacemaker. Pacing Clin Electrophysiol (1985) 1.09
Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis. Circulation (2001) 1.09
Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation (1991) 1.06
Abnormal cardiac sensitivity in patients with chest pain and normal coronary arteries. J Am Coll Cardiol (1990) 1.05
Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1992) 0.97
Results of permanent dual-chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy. Am J Cardiol (1994) 0.93
The possible relation between late pregnancy hypertension and 5-hydroxytryptamine levels in maternal blood. Br J Obstet Gynaecol (1979) 0.92
Dual chamber pacemaker therapy for mid-cavity obstructive hypertrophic cardiomyopathy. Pacing Clin Electrophysiol (2001) 0.91
Atrial synchronized ventricular pacing: contribution of the chronotropic response to improved exercise performance. Pacing Clin Electrophysiol (1983) 0.90
Ventricular septal defect after myocardial infarction: assessment by cross sectional echocardiography with pulsed wave Doppler scanning. Br Heart J (1987) 0.88
Comparison of resting hemodynamic indices and exercise performance during atrial synchronized and asynchronous ventricular pacing. Pacing Clin Electrophysiol (1983) 0.86
Sudden cardiac death in hypertrophic cardiomyopathy. Circulation (1992) 0.85
Echocardiographic detection of perforation of the cardiac ventricular septum by a permanent pacemaker lead. Am J Cardiol (1987) 0.85
Right ventricular dysfunction and surgical outcome in postinfarction ventricular septal defect. Eur Heart J (1983) 0.85
Genetic evidence of dissociation (generational skips) of electrical from morphologic forms of hypertrophic cardiomyopathy. Am J Cardiol (1990) 0.85
Regression of multiple pulmonary varices after mitral valve replacement. J Thorac Cardiovasc Surg (1980) 0.82
Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2000) 0.81
Minimum steriod requirements in renal transplant patients monitored by urinary fibrin degradation products and complement. Proc Eur Dial Transplant Assoc (1977) 0.81
A Fourier based algorithm for tracking SPAMM tags in gated magnetic resonance cardiac images. Med Phys (1996) 0.79
Effect of intravenous magnesium sulfate on blood magnesium parameters. Magnes Trace Elem (1990) 0.78
Hypertrophic obstructive cardiomyopathy: problems of management. Chest (1997) 0.77
Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation (1992) 0.77
Myocardial bridging in children with hypertrophic cardiomyopathy. N Engl J Med (1999) 0.77
Contribution of heart rate to QT interval shortening during exercise. Eur Heart J (1983) 0.77
Results of valve replacement with the Omniscience prosthesis. J Thorac Cardiovasc Surg (1983) 0.76
VT and sudden death in HCM patients. Circulation (1989) 0.75
Comparison of oxyfedrine and atenolol in angina pectoris--a double-blind study. Br J Clin Pharmacol (1985) 0.75
Comparison of single and divided daily dose spironolactone in the control of hypertension. Br J Clin Pharmacol (1981) 0.75
Wolff-Parkinson-White syndrome and sudden cardiac death. Cardiology (1987) 0.75
Comparison of vitreous carbon and elgiloy transvenous ventricular pacing leads. Pacing Clin Electrophysiol (1985) 0.75
Advances in understanding hypertrophic cardiomyopathy. Hosp Pract (1995) (2001) 0.75
Suppression of incessant ventricular tachycardia in hypertrophic cardiomyopathy associated with improvement of severe left ventricular dysfunction. Pacing Clin Electrophysiol (1992) 0.75
Raised urinary fibrin-degradation products, complement, and IgG during an influenza-like illness. Lancet (1977) 0.75
Relief of left ventricular outflow tract obstruction following inadvertent left ventricular apical pacing in a patient with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol (1995) 0.75
Experience with 407 transvenous, finned pacing leads with a sintered porous-surfaced electrode. Pacing Clin Electrophysiol (1984) 0.75
Long-term follow-up of patients with the QT rate adaptive pacemaker. Pacing Clin Electrophysiol (1989) 0.75
Radiofrequency catheter atrioventricular node ablation in patients with permanent cardiac pacing systems. Pacing Clin Electrophysiol (1994) 0.75
Urinary beta-thromboglobulin in essential hypertension. Br J Haematol (1980) 0.75
Identification of patients with hypertrophic cardiomyopathy at high risk for sudden death. Curr Opin Cardiol (1995) 0.75